DUBLIN, August 31, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment" report to their offering.
Diabetes and obesity therapeutics market will more than double to $163.2 billion by 2022.
The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%, according to the publisher.
The company's latest report states that although this growth is largely attributable to a large increase in the incidence of type 2 diabetes mellitus (T2DM) and obesity, a number of pipeline T2DM therapeutics are anticipated to be significant contributors to market growth over the forecast period, with some even expected to reach blockbuster status.
One of our analysts explains: Recent approvals and pipeline products that are expected to be key players during the forecast period include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide). The disease cluster is dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and T2DM, and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications.
While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development. Of course, the growth of the disease cluster is driven not only by the rising global incidence of obesity, but also the subsequent effect that this has on T2DM incidence, given the intrinsic link between the two diseases.
Invokana, which is marketed by Johnson & Johnson, is one of the key players in the disease cluster. It is expected to reach a huge $3.23 billion by 2022, and is set to be approved across T1DM, T2DM and obesity. Although current top-selling drugs such as Januvia, Novolog and Invokana are expected to remain dominant within the disease cluster, four of the anticipated top 10 best-selling drugs of 2022 will be new to market.
Key Topics Covered:
1 Tables & Figures
3 Key Marketed Products
4 Pipeline Landscape Assessment
5 Multi Scenario Market Forecast to 2022
6 Company Analysis and Positioning
7 Strategic Consolidations
- Novo Nordisk
- Eli Lilly
- Merck & Co
For more information about this report visit http://www.researchandmarkets.com/research/sbc29m/global_diabetes
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-billion-diabetes-and-obesity-drugs-market-2016-2022-with-novo-nordisk-eli-lilly-sanofi-merck--co-astrazeneca--takeda-dominating-the-150-billion-market-300320616.html
SOURCE Research and Markets